170 related articles for article (PubMed ID: 37513898)
1. Dissecting the Role of SMYD2 and Its Inhibitor (LLY-507) in the Treatment of Chemically Induced Non-Small Cell Lung Cancer (NSCLC) by Using Fe
Munawwar A; Sajjad A; Rasul A; Sattar M; Jabeen F
Pharmaceuticals (Basel); 2023 Jul; 16(7):. PubMed ID: 37513898
[TBL] [Abstract][Full Text] [Related]
2. LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.
Nguyen H; Allali-Hassani A; Antonysamy S; Chang S; Chen LH; Curtis C; Emtage S; Fan L; Gheyi T; Li F; Liu S; Martin JR; Mendel D; Olsen JB; Pelletier L; Shatseva T; Wu S; Zhang FF; Arrowsmith CH; Brown PJ; Campbell RM; Garcia BA; Barsyte-Lovejoy D; Mader M; Vedadi M
J Biol Chem; 2015 May; 290(22):13641-53. PubMed ID: 25825497
[TBL] [Abstract][Full Text] [Related]
3. Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas.
Kukita A; Sone K; Oda K; Hamamoto R; Kaneko S; Komatsu M; Wada M; Honjoh H; Kawata Y; Kojima M; Oki S; Sato M; Asada K; Taguchi A; Miyasaka A; Tanikawa M; Nagasaka K; Matsumoto Y; Wada-Hiraike O; Osuga Y; Fujii T
Biochem Biophys Res Commun; 2019 May; 513(2):340-346. PubMed ID: 30955858
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and structure-activity relationship studies of LLY-507 analogues as SMYD2 inhibitors.
Zhang B; Liao L; Wu F; Zhang F; Sun Z; Chen H; Luo C
Bioorg Med Chem Lett; 2020 Nov; 30(22):127598. PubMed ID: 33011288
[TBL] [Abstract][Full Text] [Related]
5. The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells.
Kojima M; Sone K; Oda K; Hamamoto R; Kaneko S; Oki S; Kukita A; Kawata A; Honjoh H; Kawata Y; Kashiyama T; Sato M; Taguchi A; Miyamoto Y; Tanikawa M; Tsuruga T; Nagasaka K; Wada-Hiraike O; Osuga Y; Fujii T
Oncol Lett; 2020 Nov; 20(5):153. PubMed ID: 32934721
[TBL] [Abstract][Full Text] [Related]
6. Magnetic chitosan nanoparticles loaded with Amphotericin B: Synthesis, properties and potentiation of antifungal activity against common human pathogenic fungal strains.
Zareshahrabadi Z; Khorram M; Pakshir K; Tamaddon AM; Jafari M; Nouraei H; Ardekani NT; Amirzadeh N; Irajie C; Barzegar A; Iraji A; Zomorodian K
Int J Biol Macromol; 2022 Dec; 222(Pt A):1619-1631. PubMed ID: 36183759
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles.
Norouzi M; Yathindranath V; Thliveris JA; Kopec BM; Siahaan TJ; Miller DW
Sci Rep; 2020 Jul; 10(1):11292. PubMed ID: 32647151
[TBL] [Abstract][Full Text] [Related]
8. Chlorambucil-Iron Oxide Nanoparticles as a Drug Delivery System for Leukemia Cancer Cells.
Hussein-Al-Ali SH; Hussein MZ; Bullo S; Arulselvan P
Int J Nanomedicine; 2021; 16():6205-6216. PubMed ID: 34526768
[TBL] [Abstract][Full Text] [Related]
9. Effects of SMYD2-mediated EML4-ALK methylation on the signaling pathway and growth in non-small-cell lung cancer cells.
Wang R; Deng X; Yoshioka Y; Vougiouklakis T; Park JH; Suzuki T; Dohmae N; Ueda K; Hamamoto R; Nakamura Y
Cancer Sci; 2017 Jun; 108(6):1203-1209. PubMed ID: 28370702
[TBL] [Abstract][Full Text] [Related]
10. Histone methyltransferase Smyd2 drives adipogenesis via regulating STAT3 phosphorylation.
Su H; Meng C; Xu J; Su Z; Xiao C; Yang D
Cell Death Dis; 2022 Oct; 13(10):890. PubMed ID: 36270984
[TBL] [Abstract][Full Text] [Related]
11. Quantitative Profiling of the Activity of Protein Lysine Methyltransferase SMYD2 Using SILAC-Based Proteomics.
Olsen JB; Cao XJ; Han B; Chen LH; Horvath A; Richardson TI; Campbell RM; Garcia BA; Nguyen H
Mol Cell Proteomics; 2016 Mar; 15(3):892-905. PubMed ID: 26750096
[TBL] [Abstract][Full Text] [Related]
12. Iron oxide nanoparticles served as the primary carrier to increase drug loading in macrophages.
Zhao K; Ruan L; Liu X; Wu L; Cao J; Shen S
Biomed Mater; 2022 Dec; 18(1):. PubMed ID: 36541487
[TBL] [Abstract][Full Text] [Related]
13. Development of paclitaxel loaded pegylated gelatin targeted nanoparticles for improved treatment efficacy in non-small cell lung cancer (NSCLC): an in vitro and in vivo evaluation study.
Gu M; Luan J; Song K; Qiu C; Zhang X; Zhang M
Acta Biochim Pol; 2021 Aug; 68(4):583-591. PubMed ID: 34355554
[TBL] [Abstract][Full Text] [Related]
14. Papain grafted into the silica coated iron-based magnetic nanoparticles 'IONPs@SiO
Nasiri R; Dabagh S; Meamar R; Idris A; Muhammad I; Irfan M; Rashidi Nodeh H
Nanotechnology; 2020 May; 31(19):195603. PubMed ID: 31978907
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib loaded PLGA and chitosan coated PLGA nanoparticles with magnified cytotoxicity against A549 lung cancer cell lines.
Alshetaili AS
Saudi J Biol Sci; 2021 Sep; 28(9):5065-5073. PubMed ID: 34466084
[TBL] [Abstract][Full Text] [Related]
16. Brigatinib loaded poly(d,l-lactide-co-glycolide) nanoparticles for improved anti-tumoral activity against non-small cell lung cancer cell lines.
Ahmed MM; Fatima F; Anwer MK; Aldawsari MF; Bhatia S; Al-Harrasi A
Drug Dev Ind Pharm; 2021 Jul; 47(7):1112-1120. PubMed ID: 34551665
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of SMYD2 Sensitized Cisplatin to Resistant Cells in NSCLC Through Activating p53 Pathway.
Shang L; Wei M
Front Oncol; 2019; 9():306. PubMed ID: 31106145
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma.
Yan L; Ding B; Liu H; Zhang Y; Zeng J; Hu J; Yao W; Yu G; An R; Chen Z; Ye Z; Xing J; Xiao K; Wu L; Xu H
Theranostics; 2019; 9(26):8377-8391. PubMed ID: 31754403
[TBL] [Abstract][Full Text] [Related]
19. Design of Lamivudine Loaded Nanoparticles for Oral Application by Nano Spray Drying Method: A New Approach to use an Antiretroviral Drug for Lung Cancer Treatment.
Öztürk AA; Namlı İ; Güleç K; Görgülü Ş
Comb Chem High Throughput Screen; 2020; 23(10):1064-1079. PubMed ID: 32209039
[TBL] [Abstract][Full Text] [Related]
20. Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2.
Galván-Femenía I; Guindo M; Duran X; Calabuig-Fariñas S; Mercader JM; Ramirez JL; Rosell R; Torrents D; Carreras A; Kohno T; Jantus-Lewintre E; Camps C; Perucho M; Sumoy L; Yokota J; de Cid R
Cancer Treat Res Commun; 2018; 15():21-31. PubMed ID: 30207284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
